influenza
one
common
infecti
diseas
endang
health
human
especi
young
children
elderli
although
vaccin
effect
mean
protect
influenza
frequent
mutat
viral
surfac
antigen
low
protect
efficaci
influenza
vaccin
elderli
slow
product
process
potenti
vaccin
suppli
shortag
pandem
signific
limit
current
vaccin
adjuv
use
enhanc
efficaci
varieti
vaccin
howev
adjuv
includ
current
influenza
vaccin
approv
unit
state
studi
found
novel
adjuv
coadministr
inactiv
influenza
vaccin
use
aqueou
formul
substanti
improv
influenzaspecif
antibodi
respons
protect
lethal
infect
mous
model
enhanc
magnitud
specif
antibodi
respons
immun
low
dose
influenza
vaccin
allow
antigenspar
formul
vaccin
induc
rapid
respons
stronger
antibodi
respons
compar
vaccin
alon
vaccin
formul
adjuv
alum
importantli
significantli
enhanc
crossreact
antibodi
respons
protect
challeng
antigen
distinct
strain
result
demonstr
effect
adjuv
acceler
enhanc
specif
antibodi
respons
induc
influenza
vaccin
allow
antigen
spare
augment
crossreact
antibodi
respons
confer
protect
antigen
distinct
strain
season
pandem
influenza
viru
infect
affect
million
peopl
worldwid
world
popul
may
suffer
influenza
given
year
prevent
influenza
trival
abbrevi
recombin
onchocerca
volvulu
activationassoci
secret
hau
hemagglutin
unit
inactiv
influenza
vaccin
tiv
wide
use
tiv
prevent
influenza
ill
healthi
adult
year
age
efficaci
low
year
influenza
strain
vaccin
match
circul
virus
due
antigen
drift
shift
thu
gener
crossreact
antibodi
import
develop
better
influenza
vaccin
addit
tiv
effect
age
popul
protect
rate
elderli
year
low
even
vaccineinduc
antibodi
specif
circul
influenza
strain
use
adjuv
proven
approach
enhanc
immunogen
protect
efficaci
vaccin
adjuv
also
shown
enhanc
crossreact
respons
furthermor
enhanc
immun
respons
adjuv
allow
antigen
spare
ie
use
lower
dose
antigen
still
effect
use
smaller
amount
antigen
reduc
vachttp
elsevi
ltd
right
reserv
effect
primari
antibodi
respons
immun
differ
dose
influenza
vaccin
mice
vaccin
differ
dose
g
tiv
without
g
influenzaspecif
antibodi
igg
plasma
week
immun
determin
elisa
use
tiv
antigen
limit
detect
lod
experi
repeat
time
micegroup
time
similar
result
p
compar
tiv
vs
tiv
dose
vaccin
cine
cost
importantli
allow
peopl
receiv
vaccin
suppli
vaccin
antigen
limit
particularli
relev
influenza
vaccin
sinc
product
egg
long
process
month
meet
sudden
demand
larg
quantiti
vaccin
outbreak
pandem
present
adjuv
commerci
avail
clinic
use
human
aluminum
salt
alum
first
adjuv
approv
unit
state
gener
use
vaccin
influenza
vaccin
commerci
avail
unit
state
europ
alumadsorb
howev
alum
remov
influenza
vaccin
formul
unit
state
earli
margin
enhanc
antibodi
respons
increas
advers
reaction
particularli
children
one
protein
adjuv
potenti
onchocerca
volvulu
activationassoci
secret
protein
recent
studi
demonstr
recombin
power
immunostimulatori
adjuv
use
ovalbumin
polypeptid
sarscov
peptid
subunit
antigen
sever
commerci
avail
vaccin
promot
balanc
antibodi
respons
cellular
respons
sever
vaccin
antigen
studi
demonstr
mous
model
substanti
enhanc
magnitud
specif
antibodi
respons
immun
low
dose
influenza
vaccin
also
acceler
antibodi
respons
furthermor
significantli
enhanc
crossreact
antibodi
respons
protect
challeng
antigen
distinct
strain
result
demonstr
promis
adjuv
use
inactiv
influenza
vaccin
enabl
vaccin
antigen
spare
enhanc
protect
influenza
infect
six
eightweekold
femal
mice
purchas
jackson
laboratori
bar
harbor
main
use
experi
mice
maintain
aaalacapprov
barrier
facil
drexel
univers
philadelphia
pa
allow
acclim
least
one
week
anim
facil
prior
use
anim
procedur
perform
studi
conduct
approv
iacuc
drexel
univers
comparison
alum
induc
influenzaspecif
antibodi
respons
primari
immun
influenza
vaccin
mice
vaccin
g
tiv
alon
tiv
combin
g
mg
alum
titer
influenzaspecif
antibodi
igg
plasma
week
immun
determin
elisa
use
tiv
antigen
data
combin
micegroup
independ
experi
similar
result
p
tiv
use
fluarix
formula
glaxosmithklin
bei
resourc
http
wwwbeiresourcesorg
contain
hemagglutinin
ha
follow
three
influenza
virus
nymc
nymc
mice
immun
intramuscularli
im
differ
dose
tiv
tiv
mix
purifi
gmous
tiv
mix
imject
alum
thermo
scientif
mgmous
influenza
apuerto
viru
strain
propag
specif
pathogenfre
fertil
chicken
egg
group
mice
challeng
intranas
day
post
primari
immun
secondari
immun
mice
anesthet
intraperiton
mg
ketamin
mg
xylazin
inocul
tcid
infect
mice
weigh
daili
lost
initi
bodyweight
euthan
accord
institut
iacuc
guidelin
influenzaspecif
antibodi
respons
measur
elisa
previous
describ
unlik
balbc
mice
mice
gene
express
differ
antibodi
crossreact
antibodi
therefor
use
provid
rel
measur
level
describ
previous
experi
purifi
ha
use
coat
provid
bei
resourc
end
point
titer
antibodi
defin
reciproc
highest
dilut
plasma
give
optic
densiti
od
greater
time
mous
plasma
sampl
unpair
twotail
student
ttest
use
determin
differ
immun
respons
group
mice
signific
surviv
rate
analyz
logrank
mantelcox
test
antibodi
titer
express
mean
sem
result
consid
statist
signific
p
valu
less
determin
could
enhanc
influenzaspecif
antibodi
respons
mice
immun
g
ha
tiv
without
g
shown
fig
week
immun
significantli
enhanc
total
igg
respons
plasma
compar
immun
tiv
alon
dose
vaccin
p
importantli
level
igg
immun
g
plu
compar
induc
g
tiv
alon
week
p
demonstr
addit
lower
dose
vaccin
could
util
gener
strong
total
igg
respons
character
antibodi
respons
measur
titer
induc
immun
titer
significantli
chang
addit
either
week
contrast
respons
significantli
enhanc
g
vaccin
week
g
week
p
result
show
addit
significantli
enhanc
influenzaspecif
total
igg
antibodi
respons
compar
vaccin
alon
alum
adjuv
licens
unit
state
gener
use
human
strongli
promot
associ
antibodi
respons
result
show
enhanc
predominantli
respons
importantli
recent
studi
suggest
respons
induc
influenza
vaccin
play
import
role
protect
influenza
therefor
compar
abil
alum
enhanc
antibodi
respons
immun
tiv
mice
immun
tiv
tiv
alum
two
week
immun
titer
total
igg
plasma
determin
elisa
fig
alum
significantli
enhanc
total
igg
level
compar
tiv
alon
p
signific
differ
total
igg
alumvaccin
mice
p
level
antibodi
significantli
higher
tiv
alum
group
tiv
alon
tiv
group
p
notabl
tiv
neither
tiv
alum
tiv
alon
induc
signific
respons
influenza
vaccin
result
demonstr
enhanc
total
igg
respons
similar
alum
elicit
signific
influenzaspecif
seen
either
tiv
alon
alum
primari
immun
immun
inactiv
influenza
vaccin
usual
take
two
week
gener
antibodi
respons
level
influenzaspecif
total
igg
plasma
undetect
week
immun
tiv
alon
howev
product
influenzaspecif
igg
significantli
acceler
upon
immun
tiv
readili
detect
week
fig
b
interestingli
titer
total
igg
tiv
group
week
similar
tiv
alon
group
week
tiv
vs
tiv
p
fig
result
demonstr
coadminist
influenza
vaccin
significantli
acceler
influenzaspecif
igg
product
primari
immun
test
whether
could
enhanc
crossreact
antibodi
respons
mice
immun
g
tiv
tiv
boost
vaccin
origin
receiv
crossreact
respons
determin
elisa
plate
coat
inactiv
viru
viru
antigen
distinct
compar
viral
strain
flurix
vaccin
crossreact
antibodi
detect
week
primari
immun
group
data
shown
howev
crossreact
igg
antibodi
found
week
secondari
immun
tiv
fig
level
igg
viru
tiv
group
significantli
higher
p
tiv
alon
group
fig
next
sought
determin
crossreact
antibodi
elicit
tiv
specif
intern
viral
protein
epitop
ha
conserv
nymc
vaccin
strain
perform
addit
elisa
use
plate
coat
purifi
ha
instead
virion
share
intern
protein
np
vaccin
strain
similar
data
elisa
coat
virion
fig
b
crossreact
antibodi
detect
primari
immun
crossreact
igg
purifi
ha
found
week
secondari
immun
tiv
tiv
alon
fig
titer
total
igg
reactiv
purifi
ha
significantli
higher
tiv
group
tiv
alon
group
p
fig
plasma
sampl
isol
primari
secondari
immun
hemagglutin
inhibit
hai
assay
neg
use
viru
data
shown
indic
crossreact
antibodi
direct
receptor
bind
domain
ha
globular
head
region
togeth
result
show
enhanc
gener
crossreact
antibodi
respons
crossreact
antibodi
target
ha
epitop
conserv
across
influenza
viru
strain
abil
enhanc
crossprotect
efficaci
influenza
vaccin
influenza
viru
challeng
examin
singl
immun
primeboost
immun
mice
immun
tiv
without
three
week
later
challeng
viru
infect
mice
three
group
tiv
tiv
pb
control
exhibit
signific
morbid
indic
loss
weight
fig
howev
mice
group
receiv
tiv
gradual
recov
eighti
percent
mice
tiv
group
surviv
wherea
mice
vaccin
tiv
alon
pb
control
succumb
infect
day
fig
recoveri
suggest
primari
immun
respons
suffici
total
prevent
influenza
infect
level
immun
gener
limit
infect
test
whether
protect
respons
could
achiev
mice
receiv
two
immun
boost
three
week
primari
immun
challeng
three
week
second
immun
mice
boost
tiv
lost
weight
peak
infect
around
day
regain
lost
weight
day
challeng
fig
addit
mice
boost
tiv
surviv
challeng
compar
surviv
one
immun
fig
surviv
rate
significantli
increas
tiv
group
compar
either
tiv
alon
pb
group
togeth
result
clearli
demonstr
significantli
enhanc
crossprotect
efficaci
low
dose
influenza
vaccin
primari
booster
immun
adjuv
approv
fda
commerci
avail
use
human
unit
state
recent
protein
adjuv
properti
name
discov
helminth
parasit
volvulu
member
famili
protein
found
freeliv
parasit
nematod
recombin
protein
molecular
weight
kd
also
angiogen
activ
mice
present
studi
demonstr
power
adjuv
immunogen
characterist
may
help
overcom
limit
current
influenza
vaccin
significantli
enhanc
total
igg
respons
compar
immun
tiv
alon
dose
influenza
vaccin
test
mous
model
importantli
low
dose
vaccin
administ
induc
total
igg
respons
level
high
higher
immun
time
higher
dose
vaccin
alon
result
demonstr
potenc
adjuv
enhanc
igg
respons
tiv
allow
dose
spare
tiv
antigen
antigen
spare
crucial
pandem
influenza
outbreak
slow
process
limit
capac
current
influenza
vaccin
product
alway
meet
sudden
need
larg
amount
vaccin
like
adjuv
mechan
enhanc
immun
respons
induc
fulli
understood
recent
report
primarili
bind
apc
induc
proinflammatori
cytokin
consist
find
observ
addit
tiv
enhanc
total
igg
significantli
respons
neither
vaccin
alon
vaccin
alum
induc
detect
amount
differ
antibodi
respons
may
respons
differ
protect
observ
challeng
lethal
dose
influenza
viru
mice
immun
influenza
vaccin
plu
provid
better
protect
immun
vaccin
alon
contrast
report
mice
immun
tiv
plu
alum
suffer
sever
weight
loss
significantli
higher
viru
load
lung
receiv
vaccin
alon
recent
studi
indic
respons
induc
influenza
vaccin
play
import
role
protect
influenza
infect
result
consist
find
suggest
respons
induc
influenza
vaccin
plu
may
play
import
role
crossprotect
influenza
infect
immun
tiv
usual
take
week
gener
antibodi
respons
result
indic
acceler
gener
igg
respons
vaccin
result
high
level
antibodi
one
week
primari
immun
particularli
advantag
unanticip
pandem
addit
time
window
avail
appropri
vaccin
start
season
epidem
short
year
due
delay
vaccin
manufactur
earli
outbreak
acceler
respons
induc
influenza
vaccin
would
offer
major
advantag
situat
ideal
influenza
vaccin
offer
broad
crossreact
immun
crossreact
antibodi
usual
target
ha
stalk
region
sinc
conserv
part
ha
result
shown
coadministr
enhanc
product
crossreact
antibodi
confer
protect
infect
caus
differ
influenza
viru
strain
unknown
effect
due
enhanc
antibodi
respons
stalk
region
ha
howev
lack
hai
posit
antibodi
viru
plasma
mice
immun
tiv
protect
mice
subsequ
influenza
infect
suggest
protect
afford
vaccin
plu
may
relat
ha
globular
head
antibodi
due
enhanc
crossreact
antibodi
target
ha
stalk
conserv
antigen
site
interest
primari
immun
tiv
plu
induc
detect
antibodi
prevent
weight
loss
challeng
result
surviv
mice
actual
similar
observ
elderli
popul
receiv
tiv
low
level
antibodi
respons
circul
influenza
viru
show
influenza
symptom
infect
influenza
viru
demonstr
less
sever
diseas
indic
fewer
hospit
nonimmun
elderli
infect
influenza
secondari
immun
elderli
tiv
annual
realist
public
health
strategi
howev
crossreact
observ
studi
demonstr
broad
base
crossreact
multipl
strain
influenza
eg
influenza
vaccin
may
need
annual
durat
crossreact
protect
afford
two
immun
tiv
plu
shown
long
last
booster
immun
tiv
plu
possibl
sinc
could
protect
multipl
strain
influenza
thu
elimin
need
annual
immun
current
test
enhanc
antibodi
respons
protect
influenza
age
mice
tiv
immun
protect
long
last
summari
report
protein
adjuv
enhanc
acceler
influenzaspecif
antibodi
respons
immun
confer
increas
protect
mous
model
enhanc
stronger
antibodi
respons
influenza
vaccin
compar
convent
adjuv
alum
enhanc
crossreact
antibodi
respons
importantli
enhanc
protect
afford
inactiv
influenza
vaccin
challeng
antigen
distinct
strain
result
clearli
demonstr
effect
adjuv
acceler
enhanc
specif
antibodi
respons
induc
influenza
vaccin
potenti
allow
antigen
spare
enhanc
heterolog
protect
